Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer
Atossa Therapeutics (NASDAQ: ATOS) endorses the U.S. Surgeon General's Advisory highlighting alcohol as a major preventable cause of breast cancer. The Advisory reveals that alcohol contributes to nearly 100,000 cancer cases and 20,000 cancer deaths annually in the US, making it the third leading preventable cause of cancer after tobacco and obesity.
Breast cancer represents the largest portion of alcohol-related cancers in women, accounting for 44,180 cases annually (16.4% of all breast cancer diagnoses). The risk begins to rise with as little as one drink per day, yet less than 45% of Americans believe alcohol significantly affects cancer development.
The Advisory calls for updated health warning labels on alcoholic beverages, expanded public education efforts, and implementation of proven alcohol reduction strategies in cancer prevention initiatives.
Atossa Therapeutics (NASDAQ: ATOS) sostiene l'Avviso del Chirurgo Generale degli Stati Uniti che evidenzia l'alcol come una delle principali cause prevenibili di cancro al seno. L'Avviso rivela che l'alcol contribuisce a quasi 100.000 casi di cancro e 20.000 decessi per cancro ogni anno negli Stati Uniti, rendendolo la terza causa prevenibile di cancro dopo il tabacco e l'obesità.
Il cancro al seno rappresenta la porzione più grande dei tumori correlati all'alcol nelle donne, con 44.180 casi all'anno (16,4% di tutte le diagnosi di cancro al seno). Il rischio inizia a aumentare con appena un drink al giorno, eppure meno del 45% degli americani crede che l'alcol influisca significativamente sullo sviluppo del cancro.
L'Avviso richiede etichette di avviso sanitario aggiornate sulle bevande alcoliche, sforzi educativi pubblici ampliati e l'implementazione di strategie di riduzione dell'alcol comprovate nelle iniziative di prevenzione del cancro.
Atossa Therapeutics (NASDAQ: ATOS) apoya el Aviso del Cirujano General de EE. UU. que resalta el alcohol como una de las principales causas prevenibles de cáncer de mama. El Aviso revela que el alcohol contribuye a casi 100,000 casos de cáncer y 20,000 muertes por cáncer anualmente en EE. UU., convirtiéndose en la tercera causa prevenible de cáncer después del tabaco y la obesidad.
El cáncer de mama representa la mayor parte de los cánceres relacionados con el alcohol en mujeres, contabilizando 44,180 casos anuales (16.4% de todos los diagnósticos de cáncer de mama). El riesgo comienza a aumentar con apenas una bebida al día, sin embargo, menos del 45% de los estadounidenses creen que el alcohol afecta significativamente el desarrollo del cáncer.
El Aviso exige etiquetas de advertencia de salud actualizadas en las bebidas alcohólicas, esfuerzos educativos públicos ampliados y la implementación de estrategias comprobadas para reducir el alcohol en las iniciativas de prevención del cáncer.
Atossa Therapeutics (NASDAQ: ATOS)는 미국 공중보건국장의 권고를 지지하며, 알코올이 유방암의 주요 예방 가능한 원인이라는 점을 강조합니다. 이 권고는 알코올이 매년 미국에서 거의 100,000종의 암 사례와 20,000건의 암 사망에 기여한다는 것을 보여주며, 담배와 비만에 이어 세 번째로 예방 가능한 암 원인으로 자리잡고 있습니다.
유방암은 여성의 알코올 관련 암 중 가장 큰 비중을 차지하며, 매년 44,180건 (전체 유방암 진단의 16.4%)의 사례가 발생합니다. 하루에 음료 한 잔만으로도 위험이 증가하기 시작하지만, 45% 미만의 미국인이 알코올이 암 발병에 큰 영향을 미친다고 믿고 있습니다.
이 권고는 알코올 음료에 대한 건강 경고 라벨의 업데이트, 확장된 공공 교육 노력, 암 예방 이니셔티브에서 입증된 알코올 감소 전략의 이행을 촉구합니다.
Atossa Therapeutics (NASDAQ: ATOS) soutient l'Avis du Chirurgien Général des États-Unis qui souligne que l'alcool est une cause majeure évitable de cancer du sein. Cet Avis révèle que l'alcool contribue à près de 100 000 cas de cancer et 20 000 décès dus au cancer chaque année aux États-Unis, ce qui en fait la troisième cause évitable de cancer après le tabac et l'obésité.
Le cancer du sein représente la plus grande part des cancers liés à l'alcool chez les femmes, avec 44 180 cas par an (16,4% de tous les diagnostics de cancer du sein). Le risque commence à augmenter avec seulement un verre par jour, pourtant moins de 45% des Américains croient que l'alcool a un impact significatif sur le développement du cancer.
L'Avis appelle à mettre à jour les étiquettes d'avertissement sanitaire sur les boissons alcoolisées, à élargir les efforts d'éducation publique et à mettre en œuvre des stratégies éprouvées de réduction de l'alcool dans les initiatives de prévention du cancer.
Atossa Therapeutics (NASDAQ: ATOS) unterstützt die Beratung des US-amerikanischen Surgeon General, die Alkohol als eine der wichtigsten vermeidbaren Ursachen für Brustkrebs hervorhebt. Die Beratung zeigt, dass Alkohol jährlich zu fast 100.000 Krebsfällen und 20.000 Krebstodesfällen in den USA beiträgt und damit die dritthäufigste vermeidbare Krebsursache nach Tabak und Fettleibigkeit ist.
Brustkrebs stellt den größten Teil der alkoholbedingten Krebserkrankungen bei Frauen dar, mit 44.180 Fällen jährlich (16,4% aller Brustkrebsdiagnosen). Das Risiko beginnt bereits bei nur einem Getränk pro Tag zu steigen, doch weniger als 45% der Amerikaner glauben, dass Alkohol einen signifikanten Einfluss auf die Krebsentwicklung hat.
Die Beratung fordert aktualisierte Gesundheitswarnhinweise auf alkoholischen Getränken, erweiterte öffentliche Bildungsmaßnahmen sowie die Umsetzung bewährter Strategien zur Alkoholreduktion in den Krebspräventionsinitiativen.
- None.
- None.
Insights
The Surgeon General's Advisory linking alcohol to breast cancer represents a significant public health milestone with broad implications. The revelation that alcohol contributes to
This Advisory could catalyze several regulatory changes: mandatory cancer warning labels on alcoholic beverages, stricter marketing restrictions and increased funding for prevention programs. These measures could reshape consumer behavior and industry practices, potentially affecting alcohol manufacturers' market performance while benefiting companies focused on cancer prevention and treatment.
While Atossa's endorsement of the Surgeon General's Advisory aligns with their corporate mission, the immediate market impact appears However, the Advisory could create long-term opportunities in the preventive healthcare space. The emphasis on alcohol as a modifiable risk factor may accelerate interest in preventive therapeutics and diagnostics, potentially benefiting companies like Atossa that focus on breast cancer prevention.
From an investor perspective, this Advisory primarily serves as validation of Atossa's strategic direction rather than a direct catalyst for stock movement. The company's market position in breast cancer prevention could strengthen as public awareness grows, but material financial impact would depend on successful development and commercialization of their preventive therapies.
SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, commends the U.S. Surgeon General for issuing a crucial Advisory that describes the scientific evidence for the causal link between alcohol consumption and increased cancer risk, particularly breast cancer in women.
The Surgeon General’s Advisory reveals that alcohol consumption contributes to nearly 100,000 cancer cases and approximately 20,000 cancer deaths in the United States each year – making it the third leading preventable cause of cancer, after tobacco and obesity. Notably, breast cancer represents the largest portion of alcohol-related cancers in women, accounting for approximately 44,180 cases annually – about 16.4 percent of all breast cancer diagnoses.
“Atossa Therapeutics fully supports the Surgeon General’s efforts to raise public awareness about alcohol’s role in increasing breast cancer risk,” said Dr. Steven Quay, M.D., Ph.D., FCAP, CEO of Atossa Therapeutics. “This Advisory aligns with our mission to prevent breast cancer before it starts. The fact that even light drinking can elevate breast cancer risk highlights the importance of education and other proactive measures to reduce alcohol-related cancers.”
The Advisory emphasizes that for certain cancers, including breast cancer, the risk begins to rise with the consumption of as little as one drink per day. Despite this evidence, less than half (45 percent) of Americans surveyed believe that alcohol consumption has a significant effect on whether the average person develops cancer.
Atossa Therapeutics echoes the Advisory’s call to action, supporting initiatives such as:
- Updating health warning labels on alcoholic beverages to reflect the cancer risk.
- Expanding public education efforts to increase awareness of alcohol’s link to breast cancer.
- Highlight alcohol consumption as a leading modifiable cancer risk factor and incorporate proven alcohol reduction strategies into population-level cancer prevention initiatives.
To further educate the public, Dr. Quay – a world-renowned physician and scientist – has released a video explaining the Surgeon General’s Advisory and what it may mean for Americans and the future of breast cancer. The video can be viewed here.
“Atossa is committed to advancing therapies aimed at reducing the burden of breast cancer. As such, we stand with the Surgeon General in advocating for public policies that inform and protect the health of women,” Dr. Quay added.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit www.atossatherapeutics.com.
FORWARD LOOKING STATEMENTS
This press release contains certain information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as “expect,” “potential,” “continue,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “plan,” “estimate,” “anticipate,” “believe,” “design,” “predict,” “future,” or other comparable words. All statements made in this press release that are not statements of historical fact, including statements regarding data related to the (Z)-endoxifen program, the safety, tolerability and efficacy of (Z)-endoxifen, the potential of (Z)-endoxifen as a breast cancer prevention and treatment agent, the expected design and enrollment of trials and timing of data and related publications, and the potential milestones and growth opportunities for the Company, are forward-looking statements. Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes, to differ materially from those projected or anticipated, including risks and uncertainties associated with: macroeconomic conditions and increasing geopolitical instability; the expected timing of releasing data; any variation between interim or preliminary and final clinical results or analysis; actions and inactions by the FDA and foreign regulatory bodies; the outcome or timing of regulatory approvals needed by Atossa, including those needed to continue our planned (Z)-endoxifen trials; our ability to satisfy regulatory requirements; our ability to remain compliant with the continued listing requirements of the Nasdaq Stock Market; our ability to successfully develop and commercialize new therapeutics; the success, costs and timing of our development activities, including our ability to successfully initiate or complete our clinical trials, including our (Z)-endoxifen trials; our anticipated rate of patient enrollment; our ability to contract with third-parties and their ability to perform adequately; our estimates on the size and characteristics of our potential markets; our ability to successfully defend litigation and other similar complaints and to establish and maintain intellectual property rights covering our products; whether we can successfully complete our clinical trial of oral (Z)-endoxifen in women with mammographic breast density and our trials of (Z)-endoxifen in women with breast cancer, and whether the studies will meet their objectives; our expectations as to future financial performance, expense levels and capital sources, including our ability to raise capital; our ability to attract and retain key personnel; our anticipated working capital needs and expectations around the sufficiency of our cash reserves; and other risks and uncertainties detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its Annual Reports on Form 10-K and Quarterly Reports on 10-Q. Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.
Contact:
Michael Parks
VP, Investor and Public Relations
484-356-7105
michael.parks@atossainc.com
FAQ
How many cancer cases are linked to alcohol consumption according to the Surgeon General's Advisory?
What percentage of breast cancer cases are related to alcohol consumption?
How much alcohol consumption increases breast cancer risk according to the Advisory?
What percentage of Americans understand the link between alcohol and cancer?
What actions does the Surgeon General's Advisory recommend to address alcohol-related cancer risk?
